70.69
Schlusskurs vom Vortag:
$68.90
Offen:
$70.465
24-Stunden-Volumen:
798.03K
Relative Volume:
0.44
Marktkapitalisierung:
$13.68B
Einnahmen:
$4.41B
Nettoeinkommen (Verlust:
$21.27M
KGV:
220.91
EPS:
0.32
Netto-Cashflow:
$288.81M
1W Leistung:
+2.11%
1M Leistung:
+5.10%
6M Leistung:
-2.54%
1J Leistung:
+7.43%
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
INCY
Incyte Corp
|
70.69 | 13.34B | 4.41B | 21.27M | 288.81M | 0.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-16 | Hochstufung | Stifel | Hold → Buy |
2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
2024-12-17 | Eingeleitet | UBS | Neutral |
2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
2024-09-18 | Herabstufung | Truist | Buy → Hold |
2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
2024-02-23 | Eingeleitet | Jefferies | Buy |
2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
2023-07-25 | Eingeleitet | Citigroup | Buy |
2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
2021-01-07 | Eingeleitet | Truist | Buy |
2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-03-24 | Fortgesetzt | William Blair | Outperform |
2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
2019-10-03 | Eingeleitet | Mizuho | Buy |
2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
2019-04-11 | Eingeleitet | Stifel | Hold |
2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional
What drives Incyte Corporation stock priceRapid capital growth - Autocar Professional
Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com
Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Incyte EVP Flannelly sells $83k in shares - Investing.com
Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte stock price target raised to $62 from $61 at UBS on sales outlook - Investing.com Canada
Sun Pharma Shares Climb 3%, Leqselvi Settlement - Rediff
Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S. - The Hindu
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp - Business Standard
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters
Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settled - The Economic Times
Sun Pharma Settles Incyte Corp Litigation - Rediff
India's Sun Pharma launches anti-baldness drug Leqselvi in US - MarketScreener
Sun Pharma settles litigation with Incyte Corp - Press Trust of India
Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance
Incyte’s Q2 2025 Earnings: What To Expect - Barchart.com
Incyte to Report Second Quarter Financial Results - Business Wire
William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey
Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN
Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Meury named Incyte CEO as Hoppenot departs - Delaware Business Times
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran” - Insider Monkey
Incyte Corporation (INCY) Announces Leadership Transition with N - GuruFocus
Bill Meury Takes Helm at Incyte (INCY) as New CEO | INCY Stock N - GuruFocus
Incyte Appoints Bill Meury Chief Executive Officer - Contract Pharma
Citi reiterates buy rating on Incyte stock amid CEO transition - Investing.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN
How Is Incyte’s Stock Performance Compared To Other Biotech Stocks? - Barchart.com
Incyte stock falls after FDA extends review of pediatric eczema cream - Investing.com
5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call - Yahoo Finance
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis - Business Wire
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Yahoo Finance
Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus
Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha
FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus
FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada
FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus
Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus
Alopecia Areata Market Expected to Experience Major Growth - openPR.com
QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):